Advaxis, Inc. (ADXS)’s Stock Insider Trade – Anthony Lombardo Sold 32 Shares; KISSEI PHARMACEUTICALS COMPANY LTD OR (KSPHF) Sellers Decreased By 0.56% Their Shorts

KISSEI PHARMACEUTICALS COMPANY LTD OR (OTCMKTS:KSPHF) had a decrease of 0.56% in short interest. KSPHF’s SI was 53,400 shares in February as released by FINRA. Its down 0.56% from 53,700 shares previously. With 100 avg volume, 534 days are for KISSEI PHARMACEUTICALS COMPANY LTD OR (OTCMKTS:KSPHF)’s short sellers to cover KSPHF’s short positions. It closed at $29.5 lastly. It is down 0.00% since February 3, 2017 and is . It has underperformed by 16.70% the S&P500.

The Interim CEO of Advaxis Inc, Anthony Lombardo has made a surprising deal in the stock exchange listed company that is having a total value $94 U.S Dollars. As stated in the D.C. based-SEC public report filed on February 2, 2018, Anthony unloaded 32 shares which is based on a market stock price per share of $2.9. Now, Anthony Lombardo owns 92,903 shares which are around 0.22% of Advaxis Inc’s total market cap.

Kissei Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in Japan. The company has market cap of $1.30 billion. The firm offers Urief tablets for the treatment of dysuria; and Glufast and Glubes tablets for diabetes; Epoetin Alfa BS injection for the treatment of renal anemia; and P-TOL chewable tablets for treating hyperphosphatemia in patients on dialysis, as well as Silodosin, a drug for the treatment of dysuria. It has a 19.51 P/E ratio. The Company’s products under pipeline includes Rovatirelin/KPS-0373 for treating Spinocerebellar ataxia; Carotegrast Methyl/AJM300 and Budesonide/AJG511 for treating Ulcerative colitis; Ozagrel/KCT-0809 for treating dry-eye with sjögrenÂ’s syndrome; and Vibegron/KRP-114V for overactive bladder that are in Phase III clinical trials.

Since September 22, 2017, it had 0 buys, and 3 insider sales for $8.07 million activity. The insider ADAGE CAPITAL PARTNERS GP – L.L.C. sold $5.47M. Shares for $16,612 were sold by Bonstein Sara on Friday, December 29.

The stock decreased 1.02% or $0.03 during the last trading session, reaching $2.9. About 861,566 shares traded or 10.07% up from the average. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since February 3, 2017 and is uptrending. It has underperformed by 5.69% the S&P500.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $120.47 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.